The Bundibugyo Ebola outbreak has reached five provinces. A treatment trial just started
Two months after the emergency declaration, confirmed cases in DRC have passed 2,100 and spread to 46 health zones. There is still no approved vaccine or treatment — but patients are now being enrolled in one.
Two months after WHO declared a public health emergency of international concern over the Bundibugyo virus disease outbreak in the Democratic Republic of the Congo, the epidemic has not slowed. As of 17 July, DRC has reported 2,124 confirmed cases and 828 deaths, a crude case fatality ratio of 39 percent [s1]. The virus has now reached 46 health zones across five provinces — Ituri, North Kivu, South Kivu, Haut-Uélé and Tshopo [s1].
There is still no approved vaccine or treatment for Bundibugyo virus disease. But as of 2 July, for the first time, patients in the outbreak zone are being enrolled in a randomized trial designed to find one [s2].
Where the numbers stand
The outbreak began in Ituri province and has since fanned out. Ituri still accounts for the largest share of cases — 27 of the province's 36 health zones have reported infections — but North Kivu (11 of 34 health zones), South Kivu (1 of 34), Haut-Uélé (4 of 13) and Tshopo (3 of 23) are all now affected [s1]. Health and care workers have borne a disproportionate share of the burden: 119 confirmed cases among them, 36 deaths, a case fatality ratio of 30.3 percent [s1].
Uganda, which reported 20 confirmed cases and two deaths earlier in the outbreak, appears to have brought its chain of transmission under control. Its most recent patient was discharged on 16 July, and the country has now entered the 42-day enhanced surveillance period WHO uses to confirm an outbreak has ended [s1].
Two cases have required international medical evacuation. A French national — a doctor who had been working in Ituri province — was confirmed positive on arrival at Charles de Gaulle Airport on 24 June and has since recovered [s1, s3]. A separate patient, a United States citizen working for a humanitarian organization in DRC, was evacuated to Germany, where the case was listed as stable as of 17 July [s1].
Why a trial is running inside an active outbreak
Unlike the Zaire ebolavirus species behind West Africa's 2014-2016 epidemic and DRC's more recent outbreaks, Bundibugyo virus has no licensed vaccine and no antiviral shown to work against it specifically [s1]. That gap is what the newly launched PARTNERS trial — Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS — is meant to close.
The trial, sponsored by WHO and run with DRC's Institut National de Recherche Biomédicale, Belgium's Institute of Tropical Medicine and the University of Oxford, with MSF and ALIMA implementing care on the ground, began enrolling patients of any age with confirmed Bundibugyo virus disease on 2 July [s2]. It is testing the monoclonal antibody MBP134, the antiviral remdesivir, and a combination of the two, against standard supportive care [s2]. Its platform design allows additional candidate treatments to be added as they become available, without having to launch a new trial from scratch [s2].
"Research needs to happen alongside the response, not after it," the trial's operations lead said in WHO's announcement, adding that the design "gives us an opportunity to evaluate potential treatments during the outbreak itself" [s2]. WHO Director-General Tedros Adhanom Ghebreyesus called the trial's speed of setup — built with national authorities and scientific partners while the outbreak was still accelerating — a source of "real hope that we can deliver concrete results for — and with — the communities at the heart of the outbreak" [s2].
At the trial's launch, WHO counted more than 1,400 diagnosed cases and roughly 440 deaths since the outbreak began [s2]. Two weeks later, the case count had grown by half again.
What answering the treatment question would change
Filovirus outbreaks have historically been managed with supportive care alone unless a matched vaccine or therapeutic already existed — as the rVSV-based vaccine did for Zaire ebolavirus by the time DRC's 2018-2020 Kivu outbreak hit its stride. Bundibugyo virus disease has never had that advantage. Case fatality has hovered near 40 percent in this outbreak, roughly comparable to historical Bundibugyo outbreaks and higher than what vaccinated, well-resourced Zaire ebolavirus responses have achieved in recent years [s1].
A positive signal from the PARTNERS trial — even a partial one, such as reduced viral load or shortened time to clearance — would be the first evidence-based treatment option this virus has ever had. A null result would still be informative: it would tell responders that repurposed filovirus drugs developed against a different ebolavirus species do not reliably cross over, sharpening the case for species-specific development.
What to watch
Whether the outbreak's geographic spread — five provinces and counting — outpaces the health system's ability to sustain contact tracing and isolation capacity in each new zone. Whether Uganda completes its 42-day surveillance window without a new case, which would let WHO declare that country's chain of transmission closed. And whether the PARTNERS trial accumulates enough enrolled patients to produce an interim readout before the outbreak, one way or another, burns out on its own.
This article is informational and does not constitute medical advice. Readers with specific health concerns related to travel to affected areas should consult official travel and health advisories.
Sources
- [s1] World Health Organization, "Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda," Disease Outbreak News, 17 July 2026. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON613
- [s2] World Health Organization, "Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease," 2 July 2026. https://www.who.int/news/item/02-07-2026-patient-enrolment-begins-in-a-scientific-trial-to-identify-the-first-effective-treatments-for-bundibugyo-virus-disease
- [s3] World Health Organization, "Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda," Disease Outbreak News, 3 July 2026. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON612
Sources
- Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — World Health Organization , July 17, 2026
- Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease — World Health Organization , July 2, 2026
- Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — World Health Organization , July 3, 2026
WHO declares a global health emergency over a rare Ebola strain with no vaccine
Eight confirmed cases, 246 suspected, and 80 suspected deaths in eastern DRC were enough for the Director-General to invoke his highest level of alarm — before convening the emergency committee that usually comes first.
DRC's Ebola outbreak reaches 5,794 cases as Uganda and France clear their monitoring
WHO's latest update records 1,129 more confirmed cases in twelve days and a case fatality ratio of 48.1%. Transmission is now confined to Congo, across 60 health zones in six provinces.
DRC's Ebola outbreak passes 100 days as death toll tops 2,500 and WHO panel reconvenes
The Bundibugyo virus epidemic is now the largest Ebola outbreak in Congo's history. WHO's emergency committee met again this week; MSF says the response still isn't reaching people fast enough.
Nearly 900 confirmed Ebola cases, and the case fatality ratio keeps climbing
Five weeks into the Bundibugyo virus emergency, WHO says some new cases reflect transmission that had gone undetected for weeks — a sign the outbreak may be larger than the count shows.